


# Analysis of Big Healthcare Databases

Rebecca Hubbard, PhD  
rhubb@upenn.edu



Perelman  
School of Medicine  
UNIVERSITY of PENNSYLVANIA

# Course Materials

All course materials can be downloaded from

**[https://rhubb.github.io/ASA\\_COC\\_short\\_course/](https://rhubb.github.io/ASA_COC_short_course/)**

This includes:

- Schedule for the day
- Slides
- Reference list
- Exercises
- Data sets used in exercises
- R code for exercise solutions

# Plan for the Day

9:00	–	9:15	Introduction
9:15	–	10:00	Overview of the structure of EHR data
10:00	–	11:00	Extracting data elements from the EHR
10:45	–	11:00	Break
11:00	–	11:30	Tutorial 1
11:30	–	12:30	Missing data issues
12:30	–	1:30	Lunch
1:30	–	2:30	Correcting for bias due to EHR data errors
2:30	–	2:45	Break
2:45	–	3:15	Tutorial 2
3:15	–	4:00	FDA's Framework for Real World Evidence and Wrap-Up

## A little bit about me...

- Began my career at Kaiser Permanente Washington Health Research Institute (formerly Group Health RI), a public interest research group in an integrated health care system
- This gave me a lot of exposure to the opportunities of using EHR data for research but also the messiness and limitations of the data
- Since then I have worked with many administrative healthcare databases including
  - ▶ Medicare (public payer claims)
  - ▶ Optum Insight (private payer claims)
  - ▶ Kaiser Permanente (integrated health system and health plan)
  - ▶ U Penn (health system, tertiary care)
  - ▶ Flatiron Health (pooled data from community cancer care)
  - ▶ PEDSnet (multi-site network of children's hospitals)

# EHR and the Real World

- EHR are one of the first “Real World Data” sources statisticians have gotten their hands dirty with
- The size of these data sets suggests enormous potential for learning about health and healthcare in real world settings.
  - ▶ Worldwide digital healthcare data is expected to reach 25 exabytes ( $10^{18}$  bytes) in 2020.
- But... with big data comes big responsibility
- That is, more data, more problems

# Electronic Health Records

## Definition


“An *Electronic Health Record (EHR)* is an electronic version of a patient’s medical history, that is maintained by the provider over time, and may include all of the **key administrative clinical data** relevant to that persons care under a particular provider, including **demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.**”

– Centers for Medicare and Medicaid Services

## Where do EHR data come from?

- Records from a single medical practice
- Records from a healthcare system including multiple practices
- Records from an integrated healthcare system including clinical data and claims
- Pooled data from multiple healthcare systems
- Regional or national databases in areas with a unified health system
- Claims data?
  - ▶ Medicare and Medicaid claims
  - ▶ Multi-payer claims databases

# Physician EHR Adoption



Office of the National Coordinator for Health Information Technology. *Office-based Physician Electronic Health Record Adoption*, Health IT Quick-Stat #50. dashboard.healthit.gov/quickstats/pages/physician-ehr-adoption-trends.php. January 2019.

- Increased clinical use of EHRs has been driven largely by the Medicare and Medicaid EHR Incentive Program
- Under this program health care providers receiving reimbursement from Medicare are incentivized to adopt EHRs
- The objective of this program was to
  - ▶ Improve quality, safety and efficiency of health care and reduce health disparities
  - ▶ Engage patients and families in care
  - ▶ Improve care coordination
  - ▶ Improve population and public health
  - ▶ Ensure privacy and security of personal health information
- Regardless of whether these goals have been met or not, the practical implication for researchers is that large amounts of observational medical data are now available.

# Objectives

- The objective of this short course is to present an overview of some of the practical challenges that arise in the analysis of EHR data and some methods to address them
- Focus is on **data structure and quality** particularly as they impact validity of research results
- Describe **strengths and limitations** of EHR data for research purposes
- Present **alternative statistical methods** to address challenges encountered in EHR data

# Outline

Overview of the structure of EHR data

Extracting data elements from the EHR

Missing data issues

Correcting for bias due to EHR data errors

FDA Framework for Real World Evidence

Conclusions

# What are the advantages of using EHR data for research?

- No need for patient recruitment or data collection
- Large sample size
- Diverse population
- Generalizability
- Potential for multi-site studies
- Cheap and “easy” access

## What are the disadvantages of using EHR data for research?


- Data quality may be poor (quantity vs quality tradeoff)
- Data collection is not systematic leading to complex missing data patterns
- Extracting data from text notes is challenging and error-prone
- Privacy protections (HIPAA) limit what data can be accessed and by whom

# Dimensions of data quality

- **Completeness:** Is a truth about a patient present in the EHR?
- **Correctness:** Is an element that is present in the EHR true?
- **Concordance:** Is there agreement between elements in the EHR, or between the EHR and another data source?
- **Plausibility:** Does an element in the EHR make sense in light of other knowledge about what that element is measuring?
- **Currency:** Is an element in the EHR a relevant representation of the patient state at a given point in time?

Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. *Journal of the American Medical Informatics Association*. 2013;20(1):144-51.


# Schematic of EHR data structure



Nature Reviews | Genetics


Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. *Nature Reviews Genetics*. 2012;13(6):395-405.

# From healthcare data to research data



- Conversion from raw healthcare data to raw research format is critical prior to analysis
- Typically need to work with a programmer or analyst with rights to access raw data, usually embedded in healthcare operations
- Refining research data prior to analysis limits volume of data, applies standardization to data elements, and reduces risks to privacy and confidentiality
- Adhere to “minimum necessary” rule
- When possible use de-identified data (no direct identifiers or HIPAA identifiers)

# EHR data provenance



## Structured data

- Many types of EHR data are available in *structured* form
- Structured data are standardized, pre-defined, computer readable data elements coded using a closed vocabulary
- For instance, procedure codes provide information on the specific health care procedures a patient has undergone
- Structured data are particularly useful for research because they can be readily manipulated and analyzed using statistical software
- They can also be combined across multiple healthcare systems using the same coding conventions.

## Some common data formats

- **Diagnosis codes** - ICD-9/10, SNOMED, issues with rule-outs, ICD-9 to ICD-10 conversion issues (many-to-many mapping, discontinuity in temporal trends spanning switch-over date of 10/1/2015)
- **Procedure codes** - CPT/HCPCS (outpatient), DRG (inpatient), date of administration vs discharge vs test performed vs results
- **Medication codes** - NDC, RxNorm, “homegrown codes”, data for prescriptions (may not be filled or taken) vs dispensings (may not be taken), does not capture OTC use

# U.S. Core Data for Interoperability (USCDI)

- Recently adopted (June 2020) standards requiring all EHR systems to adopt common, core data elements
- USCDI incorporates existing standard formats such as RxNorm, SNOMED, and LOINC
- NIH encourages researchers to leverage USCDI standard data elements
- Should lead to greater consistency and easier pooling of data from multiple EHRs

## Unstructured data

- Unstructured data consists of health care providers' narrative clinical notes
- Takes the form of text which typically requires a human reader to understand and interpret
- The Health Story Project estimates that 1.2 billion clinical documents are produced in the US each year, of which 60% are in the form of unstructured notes
- Many data elements potentially of interest for research such as family history and patient behavioral risk factors may be embedded in text notes
- Extracting these data for research use is a challenge

# Natural Language Processing

- Manually abstracting data from clinical notes is typically too labor intensive for large EHR-based studies which may include millions of patients
- Natural Language Processing (NLP) uses computerized algorithms to identify data elements of interest embedded in text notes
- NLP processes unstructured data (e.g., text notes) to identify “concepts” related to the factor of interest
- Standardized databases of health terminology such as the Unified Medical Language System link individual terms to unique biomedical concepts

# Natural Language Processing in R

- R has many tools for conducting NLP
- This can be as simple as string manipulation
- Many functions for manipulating string are included in base R installation
  - ▶ `tolower()` - convert text to lower case
  - ▶ `aspell()` - correct spelling
  - ▶ `substr()` - extract substrings
  - ▶ `regexpr()` - regular expression matching
  - ▶ `strsplit()` - splits a string (e.g. sentence) into substrings (e.g. words)
- However, for more complex settings more sophisticated tools will be necessary

# Natural Language Processing in R

- *Text Mining with R* available online at tidytextmining.com
- tm package includes more advanced tools for processing and manipulating text
  - ▶ Meyer D, Hornik K, Feinerer I. 2008. Text mining infrastructure in R. *Journal of Statistical Software*. 25(5):1-54.
  - ▶ Vignette available in package

# Natural Language Processing with CLAMP

- Clinical Language Annotation, Modeling, and Processing (CLAMP) Toolkit is software for recognition and encoding of narrative text from EHRs
- Developed at University of Texas Health Science Center
- Includes standard pipelines and supports customization via importing custom corpora designing custom pipelines
- Freely available for academic users/research purposes
- Download here: <https://clamp.uth.edu/>

# Summary of EHR data

	ICD codes	CPT codes	Laboratory Data	Medication records	Clinical Documentation
<b>Availability in EHR systems</b>	Near-universal	Near-universal	Near-universal	Variable	Variable
<b>Recall</b>	Medium	Poor	Medium	Inpatient: High Outpatient: Variable	Medium
<b>Precision</b>	Medium	High	High	Inpatient: High Outpatient: Variable	Medium-High
<b>Fragmentation effect</b>	Medium	High	Medium-High	Medium	Low-Medium
<b>Query method</b>	Structured	Structured	Mostly structured	Structured, text queries, and NLP	NLP, text queries, and rarely structured
<b>Strengths</b>	-Easy to query -Serves as a good first pass of disease status	-Easy to query -High precision	-Value depends on test -High data validity	Can have high validity	Best record of what providers thought
<b>Weaknesses</b>	-Disease codes often used for screening when disease not actually present -Accuracy hindered by billing realities and clinic workflow	-Most susceptible to missing data errors (e.g., performed at another hospital) -Procedure receipt influenced by patient and payer factors external to disease process	-May need to aggregate different variations of the same data elements -Normal ranges and units may change over time	-Often need to interface inpatient and outpatient records -Medication records from outside providers not present -Medications prescribed not necessarily taken	-Difficult to process automatically -Interpretation accuracy depends on assessment method -May suffer from significant "cut and paste" -Not universally available in EHRs -May be self-contradictory
<b>Summary</b>	Essential first element for electronic phenotyping	Helpful addition if relevant	Helpful addition if relevant	Useful for confirmation and a marker of severity	Useful for confirming common diagnoses or for finding rare ones

doi:10.1371/journal.pcbi.1002823.t001

Denny JC. Mining electronic health records in the genomics era. *PLoS Computational Biology*. 2012;8(12):e1002823.

## PEDSnet: A multi-site network example

- PEDSnet: A PCORI-funded consortium of 8 children's hospitals
  - ▶ Includes data collected in routine clinical encounters for ~5 million children
- Investigated pediatric Type 2 Diabetes Mellitus (T2DM) in a high risk cohort:
  - ▶ Children age 10-18 years, at least two clinical encounters between 2001-2017
  - ▶ On at least one occasion BMI z-score in excess of the 95th percentile for age and sex
  - ▶ Cohort consisted of 68,265 children

# PEDSnet T2DM cohort

	Total N = 68,265	T2DM Codes or Biomarkers	
		Yes N = 804	No N = 67,461
		N (%)	N (%)
Male	36836 (53.96)	221 (27.49)	36615 (54.28)
White	35740 (52.35)	371 (46.14)	35369 (52.43)
Endocrinologist	5338 (7.82)	510 (63.43)	4828 (7.16)
Metformin	764 (1.12)	675 (83.96)	89 (0.13)
Insulin	727 (1.06)	154 (19.15)	573 (0.85)
T2DM Codes	275 (0.4)	221 (27.49)	54 (0.08)
Any glucose measurement	11325 (16.59)	355 (44.15)	10970 (16.26)
Any HbA1c measurement	6031 (8.83)	397 (49.38)	5634 (8.35)
	Mean (SD)	Mean (SD)	Mean (SD)
Age	11.90 (2.50)	13.79 (2.58)	11.87 (2.49)
BMI z-score	2.02 (0.30)	2.27 (0.36)	2.012 (0.30)
Glucose	94.309 (32.51)	141.39 (104.47)	92.79 (27.44)
Hemoglobin A1c	5.79 (1.25)	6.93 (1.94)	5.71 (1.15)

## Fit for Use

- “Fit for use” means that the data should be of appropriate quality for the use we intend to put them to.
- Almost all data sources are imperfect in one respect or another.
- The relevant question is whether they are good enough for the purposes we intend to use them for.
- For example, if we are interested in studying the association between practicing yoga and blood pressure, EHR data are probably not fit for this use.
  - ▶ No structured data elements capture practice of yoga
  - ▶ Text notes are unlikely to systematically records yoga

- On the other hand, if we want to study rates of uptake of HPV testing for cervical cancer screening EHR data may be fit for this use.
  - ▶ Procedure codes capture HPV testing
  - ▶ Since a procedure code must be recorded in order for the provider to be reimbursed capture is likely to be relatively complete
- As we discuss EHR data and its analysis it is important to keep in mind that the relevance of a given issue will depend on the specific research question and the data needed to answer that question.

- Throughout this course we will use a synthetic (i.e., fake) EHR-derived data set based on the structure of the PEDSnet dataset to explore some of the challenges of EHR data and strategies for dealing with them we will be discussing
- The PEDSnet synthetic data sets and R code for working with them are available at [https://rhubb.github.io/ASA\\_CoC\\_short\\_course/](https://rhubb.github.io/ASA_CoC_short_course/)
- These data sets were generated by sampling from the distributions of data elements contained in the real PEDSnet data
- The result is a set of data sets that reflect the features of the PEDSnet data but avoid issues of privacy protection that accompany real EHR-derived data

# Outline

Overview of the structure of EHR data

**Extracting data elements from the EHR**

Missing data issues

Correcting for bias due to EHR data errors

FDA Framework for Real World Evidence

Conclusions


# Rule-based Phenotyping

- Most of the existing literature on EHR-derived phenotyping relies on “clinical decision rules”
  - ▶ Simple or complex
  - ▶ Including one data element or many
  - ▶ May include a time component
- Algorithm based on clinical knowledge of the disease and coding practices
- May incorporate structured data as well as unstructured data, often via NLP
- Sometimes validated against gold-standard diagnosis data

## Example: Rule-based Phenotyping for T2DM


Variable type	Examples	Format
Diabetes diagnosis	<ul style="list-style-type: none"><li>• T2DM</li><li>• T1DM</li><li>• DM NOS</li></ul>	ICD-9/10 codes
Medications	<ul style="list-style-type: none"><li>• Insulin</li><li>• Metformin</li></ul>	Prescribing data
Co-morbidities	<ul style="list-style-type: none"><li>• PCOS</li><li>• Obesity</li></ul>	ICD-9/10 codes
Biomarkers	<ul style="list-style-type: none"><li>• Glucose</li><li>• HbA1c</li></ul>	Procedure codes for test administration; numerical results

# Agreement among TD2M variables



Adapted from Richesson et al. *J Am Med Inform Assoc* 2013;20:e319-e326.

# Example: T2DM Rule



Kho et al. J Am Med Inform Assoc 2012;19:212-218

# Typical process for EHR-based phenotype development

- Clinical experts develop a list of potential variables
  - ▶ May include condition of interest, symptoms, co-morbidities, common treatments
- Translate list into corresponding structured codes (e.g., ICD-9/10, CPT)
- NLP experts map terms to UMLS concepts
- Extract all occurrences of demographics, codes of interest, biometric data, and laboratory test results from structured data
- Apply NLP to unstructured (narrative text) data

## PEDSnet Example

age	race	zBMI	HbA1c	Glucose	T2DM	FamHx	Endo
11	0	1.658355	NA	NA	0	0	0
12	0	1.996588	NA	119.54555	0	0	0
14	1	2.057993	5.949531	98.69711	0	0	0
18	0	2.508225	5.137229	82.54253	0	0	0
11	1	1.820784	NA	NA	1	0	0
17	1	2.547955	5.622635	85.22707	0	0	0

# Classification

- Once data have been extracted from the EHR a classification algorithm can be applied to the individual data elements to create a construct of interest
- Gold standard information for supervised learning approaches extracted via manual chart abstraction
- Classification approaches applied to EHR data range from the very simple to the very complex
  - Dichotomous classification based on presence/absence of data elements based on clinical judgment
  - Prediction modeling, e.g. CART, LASSO
  - Machine learning algorithms, e.g. random forests, neural networks
- Performance is typically evaluated based on PPV and NPV relative to gold standard
- Implications of low prevalence for PPV/NPV

## Using validated phenotypes

- Ideally, only validated phenotypes should be used
- Validation requires manual chart abstraction and hence can be costly and slow
- Many validated phenotypes are available, for instance, via PheKb (<https://phekb.org>)
- However, be cautious about assuming that operating characteristics will be the same in your data set as they were in the derivation data set (i.e., lack of portability)

# Tutorial 1

# Outline

Overview of the structure of EHR data

Extracting data elements from the EHR

**Missing data issues**

Correcting for bias due to EHR data errors

FDA Framework for Real World Evidence

Conclusions

## Missing data in EHR

- Because EHR data are not collected according to a research protocol they will often be missing variables of interest
- While missing data are virtually ubiquitous in EHR-based studies, a critical first step to dealing with missingness is consideration of what constitutes a “complete” record
- Unlike a designed observational study, there is no prior specification of which data elements should be collected for a patient or when they should be collected
- Before we can quantify the magnitude of the missing data problem for a given study we need to define the data we wish to have
- Often useful to consider the data that we would have collected had we designed a study protocol and collected the data ourselves


## PEDSnet Example

- Objective: Study risk factors for T2DM in children
- Longitudinal study of time to T2DM diagnosis
- Covariates:
  - ▶ Time-varying measures of BMI, physical activity, diet, co-morbidities
  - ▶ Age at diagnosis of T2DM
- If this is our desired study objective and design, which of these data elements can be derived from the EHR and how much missingness will they have?

## PEDSnet Example

- Patients assessed irregularly; must decide on a frequency of observation for BMI that is “good enough”
- Behavioral risk factors rarely collected, not in structured data; may be able to extract from notes with NLP but will be frequently missing
- Age at diagnosis determined based on application of a phenotyping algorithm; depending on algorithm may be missing for patients with missing biomarker data or infrequent clinical assessment

# BMI data collection




Haneuse and Daniels. 2016. *eGEMS* 4(1):16.

## Missingness mechanisms

- Once we have decided on which data we need for our study we can evaluate missingness
- Next step is to consider causes of missing data
- Haneuse and Daniels recommend thinking about why data are *observed* rather than why data are missing
- Missingness mechanism will likely reflect interplay of patient risk factors and disease conditions, patient behavior, provider clinical practices, and healthcare system administrative practices (**data provenance**)


## MAR missingness mechanism



- Patients with risk factors for T2DM more likely to be screened
- Risk factors more strongly associated with missingness for more definitive biomarkers (FPG, HbA1c)

# MNAR missingness mechanism

- Missingness likely depends on underlying T2DM status directly
- Risk factors may influence missingness through T2DM (symptoms) or directly (screening)
- Patients' interaction with the healthcare system also affects observation process




## PEDSnet example: Missingness in glucose

	OR	95% CI	p
Age at baseline (years)	0.89	(0.88, 0.90)	<0.001
Baseline year	1.02	(1.02, 1.03)	<0.001
Male	1.14	(1.09, 1.19)	<0.001
Race			
Black	0.83	(0.79, 0.87)	<0.001
Native American	0.60	(0.33, 1.11)	0.106
Asian	0.90	(0.75, 1.08)	0.280
Other	0.57	(0.52, 0.62)	<0.001
Unknown	1.39	(1.25, 1.54)	<0.001
Ethnicity			
Hispanic	0.81	(0.75, 0.88)	<0.001
Endocrinologist visit	0.23	(0.21, 0.24)	<0.001
Metformin	0.30	(0.26, 0.35)	<0.001
Insulin	1.10	(0.86, 1.40)	0.454
BMI	0.69	(0.66, 0.73)	<0.001
T1D codes	0.91	(0.73, 1.14)	0.404
T2D codes	0.59	(0.45, 0.77)	<0.001

# Missingness modules

- Considering missingness mechanism as a series of conditional steps may help in assessment of MAR assumption (Haneuse & Daniels, 2016)



## Analysis strategies in the presence of missingness

- Under MAR mechanisms can use multiple imputation (MI) or inverse probability weighting (IPW)
- Many software packages available for implementation
- In Multivariate Imputation via Chained Equations (MICE) a separate regression model is specified for each variable with missing observations
- Missing data in each variable are sequentially filled in and subsequently used in regression models for other variables
- This process is iterated until parameter estimates are stable
- Predictions are then generated from the final set of models for all missing observations

- MICE is convenient for use with EHR data because regression models for each variable can allow for different variable types and can include different predictors
- However, the process of model specification can be quite laborious
- Additionally, MICE is somewhat ad hoc in that the set of conditional models for each variable may not correspond to a joint model for all variables
- Computationally intensive for large EHR samples
- Available in many software packages including the `mice` package for R

## Loss to follow-up in EHR

- A challenging aspect of longitudinal studies using EHR is that we may not know when patients have left the healthcare system
- Claims databases provide an indicator of enrollment that can be used to censor patients who disenroll
- A variety of ad hoc approaches have been proposed including
  - ▶ Censoring patients at a fixed timepoint (e.g. 1 year) after last clinical encounter
  - ▶ Restrict cohort to patients with some level of interaction with healthcare system (Lin KJ, et al. Identifying patients with high data completeness to improve validity of comparative effectiveness research in electronic health records data. *Clinical Pharmacology & Therapeutics*. 2018;103(5):899-905.)
- Care must be taken to avoid immortal time bias

## A case study of missing outcome data

Carrigan G, et al. 2019. An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database. *Pharmacoepidemiology and drug safety*. doi:10.1002/pds.4758


- Used data from the Flatiron Health database of community oncology centers and gold-standard death data from National Death Index to investigate effect of missing information on mortality on hazard ratio estimates
- Missing outcomes substantially inflated estimates of median survival time but had little effect on hazard ratios
- However, using EHR data as external control arm resulted in significant bias
- Implications for between-site comparisons if loss to follow-up patterns differ

## Biased sampling in EHR data

- Complex observation patterns also arise in terms of the number of observations per subject in EHR data
- In EHR data, some members of the target population are more frequently observed than others
  - ▶ Co-morbidity and health outcomes: patients with co-morbidities that require regular monitoring (e.g. diabetes, kidney disease) have more frequent contact with healthcare system; capture health outcomes data more frequently and accurately
  - ▶ Screening test performance: patients experiencing symptoms of the disease of interest more likely to come in for screening tests
- If intensity of interaction with the healthcare system is related to the disease of interest, this results in an informative observation scheme, violating the assumptions of many standard statistical methods

# Informative observation processes

- Intensity of healthcare utilization can be considered a marker of health
- In this case, patients with many visits may be systematically different from those with few
- One way to deal with this is to condition on number of encounters
- This has been shown to effectively account for informative observation processes in some cases, but can induce M-bias



Goldstein BA et al. Controlling for informed presence bias due to the number of health encounters in an electronic health record.  
*Am J Epidemiol.* 2016 Dec 1;184(11):847-55.

# Outline

Overview of the structure of EHR data

Extracting data elements from the EHR

Missing data issues

Correcting for bias due to EHR data errors

FDA Framework for Real World Evidence

Conclusions

## Issues arising in the analysis of EHR-derived phenotypes

- Regardless of the approach to phenotyping, some residual error will typically remain
- Statistical methods for misclassified outcomes can be adapted to this context
- Some additional challenges in the context of EHR-based research arise due to limited access to validation data
- Accuracy parameters for phenotypes may also exhibit lack of transportability
- We will discuss some alternative approaches to these challenges

## Example: Error in EHR derived SBCE dates

- Use of EHR data-based algorithms to identify event times may introduce error in
  - ▶ Classification as to whether or not an event occurred
  - ▶ Exact timing of event
- **Example:** Second breast cancer event (SBCE) in women with a history of breast cancer
  - ▶ Algorithm identifies SBCE with  $Se = 89\%$ ,  $Sp = 99\%$
  - ▶ Can algorithm be used to identify date of SBCE?
  - ▶ What are implications for estimates of exposure/outcome associations if imperfectly ascertained outcomes are used?


## Second breast cancer events

- BRAVA study developed algorithm to identify SBCEs using a combination of cancer registry and EHR data
- Validated against manual chart review
- We explored how well dates assigned based on this algorithm agreed with gold-standard
- 407 chart-reviewed SBCEs, 358 (88%) identified by algorithm


# High specificity algorithm

Two visits with a code for a secondary malignant neoplasm  
within 60 days and occurring >365 days after the primary breast  
cancer

(n = 1 892)



## Error in date assignment for SBCE



- 82% of events were within 60 days of algorithm-based date
- Is this good enough?

Chubak J et al. An Electronic Health Record–based Algorithm to Ascertain the Date of Second Breast Cancer Events. *Medical Care*. 2017;55(12):e81-7.

## Using the EHR to study novel exposures

- EHRs provide the opportunity to identify novel risk factors for disease incidence or outcomes
- Cancer registry data collection is narrowly focused on cancer characteristics and treatment
- EHR allows us to explore a variety of novel risk factors such as treatments for other conditions and co-morbidities
- However, EHR-derived outcomes may exhibit exposure-dependent differences in data quality
  - ▶ Only observe the outcome if documented at a healthcare encounter (higher sensitivity among exposed)
  - ▶ Patients interacting with the healthcare system also have more opportunity for erroneous codes to appear in charts (lower specificity)
- If EHR is used for discovery, screening many potential risk factors, type I error is of particularly high concern

## Simulation study for imperfect time to event outcomes

- Conducted a simulation study with event and error rates for dates motivated by SBCE study
- Estimated HRs using imperfectly assigned SBCE dates and compared to true HRs used to simulate data

Sensitivity/specificity	Error in date
Non-differential	Non-differential
Non-differential	Later event detection in exposed
Non-differential	Earlier event detection and less variability
Non-differential	Later event detection and more variability
Higher sensitivity/lower specificity	Non-differential
Higher sensitivity/lower specificity	Earlier event detection and less variability

## Simulation study for imperfect time to event outcomes

Sensitivity/specificity	Error in date	% Bias in HR
Non-differential	Non-differential	-2.2
Non-differential	Later event detection in exposed	0.4
Non-differential	Earlier event detection and less variability	-0.9
Non-differential	Later event detection and more variability	-3.8
Higher sensitivity/lower specificity	Non-differential	6.5
Higher sensitivity/lower specificity	Earlier event detection and less variability	8.1

## Type I error due to outcome misclassification

- In addition to bias, inflated type I error rates are of high importance as they indicate the frequency of spuriously identified risk factors
- Using BRAVA data on the EHR-derived outcome and patient and cancer characteristics, we simulated an exposure variable ( $E$ ) that was independent of the outcome
- Let  $a_{jk} = P(S = 1|D = j, E = k)$  represent exposure-specific sensitivity and 1-specificity
- Simulating  $E$  from a Bernoulli distribution with probability


$$P(E = 1|S = i, D = j) = \frac{a_{j1}^i(1 - a_{j1})^{1-i}P(E = 1)}{\sum_{k=0,1} a_{jk}(1 - a_{jk})P(E = k)}$$

induces exposure-dependent outcome misclassification

## Type I error due to outcome misclassification

- We then analyzed the association between  $S$  and  $E$  using logistic regression
- We varied  $a_{10} - a_{11}$  and  $a_{00} - a_{01}$  (the difference in sensitivity and specificity between exposed and unexposed) across a range of values, with  $a_{10}$  fixed at 0.85 and  $1 - a_{00}$  fixed at 0.9.
- Each scenario was repeated 1,000 times
- Type I error was computed as the proportion of hypothesis tests rejected at the  $\alpha = 0.05$  level across the 1,000 simulations

# Type I error results



- Holding specificity equal in exposed and unexposed individuals, when sensitivity was 10% higher in exposed individuals compared to unexposed (i.e., 0.95 vs 0.85) the type I error rate increased to 14%.
- Similarly, holding sensitivity equal between the two groups, a 10% decrease in specificity between exposed and unexposed individuals (i.e., 0.80 vs 0.90) resulted in a type I error rate of 33%.


Chen Y et al. *Pharmacoepidemiology & Drug Safety*. 2019 Feb;28(2):264-8.

# What can we do about phenotyping error?


- Phenotyping error can lead to substantial bias and inflated type I error
- How can we obtain unbiased estimates in association analyses using EHR-derived phenotypes?
- Challenges in the EHR setting
  - ▶ Validation data are costly to obtain and in many cases completely unavailable
  - ▶ Phenotyping accuracy is often unknown and may vary widely between derivation data set and other data sets

# The bias variance tradeoff in big data

Effects of bias and random error on study results



# Data Structure



# Classic approach to outcome misclassification

- One binary predictor ( $X$ )
- Misclassified binary outcome ( $S$ )
- Known sensitivity ( $\theta$ ) and specificity ( $\phi$ );  $0 < \theta, \phi < 1$

		Classified as	
		Diseased	Not diseased
Exposed	Exposed	a	b
	Not exposed	c	d

## Classic approach to outcome misclassification

- Naive:  $\widehat{OR}_{standard} = (ad)/(bc)$
- Misclassification adjusted:  $\widehat{OR} = \frac{a/(a+b)-(1-\phi)}{c/(c+d)-(1-\phi)} \times \frac{\theta-c/(c+d)}{\theta-a/(a+b)}$
- Note that

$$\begin{aligned}\widehat{OR} &> \widehat{OR}_{standard} \text{ if } \widehat{OR}_{standard} > 1 \\ \widehat{OR} &< \widehat{OR}_{standard} \text{ if } \widehat{OR}_{standard} < 1\end{aligned}$$

Magder LS, Hughes JP. 1997. Logistic regression when the outcome is measured with uncertainty. *Am J Epidemiol.* 146(2):195-203.

# Extension to logistic regression

## Definition

**Non-differential misclassification**

**Let  $Y$  = true outcome,  $S$  = surrogate outcome**

**$S \perp X|Y$ , or equivalently**

$$\theta = P(S = 1|Y = 1, X) = P(S = 1|Y = 1),$$

$$\phi = P(S = 0|Y = 0, X) = P(S = 0|Y = 0)$$

## Extension to logistic regression

- Assume non-differential misclassification
- Let  $P(Y_i = 1) = \text{expit}(\beta^T X_i)$  then by Bayes rules
  - ▶  $\hat{P}(Y_i = 1|S_i = 1) = \frac{\theta \text{expit}(\beta^T X_i)}{\theta \text{expit}(\beta^T X_i) + (1-\phi)(1 - \text{expit}(\beta^T X_i))}$
  - ▶  $\hat{P}(Y_i = 1|S_i = 0) = \frac{(1-\theta)\text{expit}(\beta^T X_i)}{(1-\theta)\text{expit}(\beta^T X_i) + \phi(1 - \text{expit}(\beta^T X_i))}$
- An EM algorithm to estimate  $\beta$ 
  1. Perform weighted logistic regression, each subject included as both diseased and non-diseased with weights  $\hat{P}(Y_i = 1|S = k)$
  2. Update weights using new values for  $\hat{\beta}$
  3. Return to (1)

# Augmented estimation using validation data

	SBCE status (True Phenotypes, Y)	SBCE status (Surrogate, S)	year	age	stage	ER_PR	
Validation set, V (size = n)	0	0	1996	55.4	1	3	
	1	0	1995	67.9	1	1	
	1	1	2003	84.7	2	1	
	0	0	2004	46.3	1	1	
	0	1	1996	54.2	1	1	
	.	.	.	.	.	.	
	.	.	.	.	.	.	
	.	.	.	.	.	.	
Full cohort, F (size = N)		0	1999	48.5	1	2	
		1	2002	41.0	2	2	
		1	1999	32.6	1	1	
		0	2004	82.9	1	3	
	?	1	2004	72.7	1	1	
	?	0	2001	42.4	1	1	
	?	1	1994	31.7	1	1	
	?	0	1998	38.2	2	2	
	?	0	2000	34.8	1	1	
	?	0	2006	63.2	1	3	
	.	.	.	.	.	.	
	.	.	.	.	.	.	
	.	.	.	.	.	.	

Legend:  
Light gray box: Not available  
Dark gray box: Available

## Features of augmented estimation

- Requires validation data for a subset of study population
- Accommodates differential and non-differential misclassification
- No need for explicit misclassification model
- Improves efficiency of estimation relative to analysis of gold-standard outcome alone

## Augmented estimation procedure


- Three models for outcome/exposure association:
  - ▶ **Model 1:**  $Y_V \sim \beta_V X_V$
  - ▶ **Model 2:**  $S_F \sim \gamma_F X_F$
  - ▶  $S_V \sim \gamma_V X_V$
- **Model 3:** Standard misclassification correction using marginal sensitivity ( $\theta$ ) and specificity ( $\phi$ ) (Magder & Hughes, *Am J Epidemiol.* 1997;146:195–203.)
- **Model 4:** Augmented estimator

$$\hat{\beta}_A = \hat{\beta}_V - \hat{\Omega} \hat{\Sigma}^{*-1} (\hat{\gamma}_V - \hat{\gamma}_F)$$

where  $\hat{\Omega}, \hat{\Sigma}^*$  are covariance matrices.

- Compare performance varying validation sample size and algorithm operating characteristics using BRAVA data

# Performance across sample sizes and phenotypes



## An approach for predicted probabilities

- Increasingly, phenotyping uses statistical or machine learning approaches that provide probabilistic phenotypes,  $\hat{p}$
- Sinnott et al. 2014 developed a bias correction approach for analyses using these predicted probabilities as outcomes
- Suppose we wish to estimate the association between a phenotype,  $Y$ , and exposure,  $Z$  adjusting for confounders  $W$

$$g(P(Y = 1|Z, W)) = \alpha + \beta Z + \gamma W.$$

- Let  $f(\hat{p}) = (\hat{p} - \mu_0)/(\mu_1 - \mu_0)$ , where  $\mu_k = E(\hat{p}|Y = k)$
- Sinnott et al. showed that regressing  $f(\hat{p})$  on  $Z$  and  $W$  provides consistent estimates for regression coefficients.

Sinnott et al. 2014. Improving the power of genetic association tests with imperfect phenotype derived from electronic medical records. *Human Genetics*. 133:1369-82.

## A simple bias correction for risk differences

- In the context of risk difference regression in which the link function,  $g(\cdot)$ , is the identity link, this approach gives rise to a very simple bias correction

$$\begin{aligned} E(f(\hat{p})|Z, W) &= \alpha + \beta Z + \gamma W \\ E[(\hat{p} - \mu_0)/(\mu_1 - \mu_0)|Z, W] &= \alpha + \beta Z + \gamma W \\ E[\hat{p}|Z, W] &= \alpha^* + (\mu_1 - \mu_0)(\beta Z + \gamma W) \\ E[\hat{p}|Z, W] &= \alpha^* + \beta^* Z + \gamma^* W \end{aligned}$$


- Therefore,  $\hat{\beta} = \frac{\hat{\beta}^*}{\mu_1 - \mu_0}$  is unbiased for  $\beta$
- By using a Taylor series expansion to linearize  $g(\cdot)$  bias correction formulas can be obtained for other link functions including log and logistic.

Hubbard et al. 2020. Reducing bias due to outcome misclassification in epidemiologic studies using EHR-derived probabilistic phenotypes. *Epidemiology*. 31(4):542-50.

## One additional complication

- Unfortunately, in the EHR context  $\mu_0$  and  $\mu_1$  will only be available in data sets with validation data
- In the data set initially used to develop the phenotype this will be straightforward to calculate by taking the mean of  $\hat{p}$  among cases and controls
- In data sets without validation data we typically have access to published validation results, typically including a proposed cutpoint,  $p^*$ , along with sensitivity and specificity for the dichotomized phenotype
- Using this information we can obtain estimates  $\hat{\mu}_0$  and  $\hat{\mu}_1$


# Estimating $\mu_0$ without validation data




# Simulation study design

- Compared
  1. Gold standard true phenotype
  2. Dichotomized phenotype based on predicted probability
  3. Bias correction using estimated  $\hat{\mu}_0$  and  $\hat{\mu}_1$
  4. Bias correction using true  $\mu_0$  and  $\mu_1$
- Varying: AUC of  $\hat{p}$ , strength of effect ( $\beta$ ), prevalence of Y

# Bias: Prevalence = 0.5




# Bias: Prevalence = 0.1



## Application to PEDSnet data

- Applied this approach to data from the PEDSnet network
- Previously developed phenotype probability for T2DM
- Prevalence estimated at 1.5%
- Based on latent class model so no sensitivity and specificity available
- In this setting can look at results across a range of values for sensitivity and specificity as a sensitivity analysis

# Sensitivity analysis for PEDSnet



# Tutorial 2

# Outline

Overview of the structure of EHR data

Extracting data elements from the EHR

Missing data issues

Correcting for bias due to EHR data errors

FDA Framework for Real World Evidence

Conclusions

- The 21st Century Cures Act was designed to accelerate medical product development
- This included identifying ways to use RWE to approve a new indication for a drug or satisfy post-approval study requirements
- RWD (principally EHR data) can be used in many ways in medical product development
  - ▶ Hypothesis generation
  - ▶ Identifying novel risk factors
  - ▶ Assessing trial feasibility
  - ▶ Defining inclusion/exclusion criteria and baseline characteristics
  - ▶ Informing prior probability distributions for Bayesian models
  - ▶ Assembling geographically distributed research cohorts for rare diseases
  - ▶ Generating evidence on product safety
  - ▶ **Generating evidence on product effectiveness**

# Healthcare systems as a research laboratory

- In addition to conducting observational research using EHR data, a major objective of developing healthcare system-based research networks is creation of a platform for conducting pragmatic clinical trials
- Research networks comprised of healthcare systems have the potential to
  - ▶ Rapidly identify eligible patients through common data architecture
  - ▶ Implement randomization and intervention deployment through EHR
  - ▶ Provide efficient and complete outcome ascertainment through EHR
- Examples of existing networks with infrastructure to support pragmatic trials include PCORnet and the Health Care Systems Research Collaboratory
- Many single systems also support this type of research

# The Learning Healthcare System

## Definition

“Science, informatics, incentives, and culture are aligned for continuous improvement and innovation, with best practices seamlessly embedded in the delivery process and new knowledge captured as an integral by-product of the delivery experience.” IOM 2015

- Assemble the data from various sources
- Analyze the data by various means
- Interpret the findings
- Feed findings back into the system
- Change practice

<http://www.learninghealthcareproject.org/section/evidence/25/50/professor-charles-friedman-interview>

# What is a pragmatic clinical trial (PCT)?

Pragmatic clinical trials are designed to generate evidence that directly informs healthcare policy and practice by

- Investigating questions relevant to stakeholders
- Taking place in real-world clinical settings
- Collaborating with healthcare providers and organizations

## Common features of PCTs

- Use of EHRs to identify eligible patients, implement interventions and collect outcomes
- Randomization based on real-world health care operations
  - ▶ Example: notification systems embedded in EHR
- Often lends itself to cluster randomization

# Issues in the design and analysis of pragmatic clinical trials

- Sufficient sample size available
- Intervention can be implemented without impeding clinical workflow
- All sites have adequate data collection capabilities
- Organizational stakeholders support trial goals

# Cluster-randomized trials

- In the context of healthcare systems-based trials cluster randomized trials are often preferred
- Cluster randomization addresses the issue of contamination
  - ▶ If a provider or clinic treats both intervention and control patients, some elements of intervention may also reach control patients
  - ▶ Results in bias towards null
- Providers, clinics, or even entire healthcare systems serve as natural units for randomization

# Considerations for cluster-randomized trials

- Patients may be seen by more than one provider
  - ▶ To minimize contamination patients should be nested within clusters (providers, panels, clinics, etc)
  - ▶ Maximizing power requires a tradeoff between number of clusters and risk of contamination
- Power and sample size calculations must account for within-cluster correlation
- Analytic methods must be appropriate for small number of clusters

## Example: STOP CRC

Coronado et al. 2014. Strategies and opportunities to STOP colon cancer in priority populations: design of a cluster-randomized pragmatic trial. *Contemporary clinical trials*. 38(2):344-9.

- Cluster-randomized pragmatic clinical trial of effectiveness of mailed FIT kits to improve uptake of CRC screening
- Randomization at clinic level
  - ▶ 26 clinics in 8 healthcare systems
  - ▶ Power calculations based on 5850 patients per arm
- Intervention implemented in clinic EHR's identifies eligible patients
- Outcome data on uptake of CRC screening collected from EHR

# Using RWD for post-marketing safety surveillance

- EHR data have been used for some time to support post-marketing safety surveillance
- FDA's Sentinel System consist of 18 data partners (integrated healthcare systems and claims databases) including over 100 million patients
- Sentinel is a distributed network
  - ▶ Data are held locally by each partner using a common data model
  - ▶ Queries are developed to investigate safety signals
  - ▶ Query is run locally against each site's data
  - ▶ Results are pooled at a central coordinating center

## Using RWD to generate evidence on effectiveness

- Establishing evidence of effectiveness using EHR data is more challenging
- Observational studies typically have too many sources of potential bias to be relied upon in the regulatory process, confounding by indication particularly problematic
- Pragmatic clinical trials embedded in healthcare systems can be used
- In rare cases, FDA has approved a new product based on historical control arm data from EHR
  - ▶ Only applies in oncology or rare disease settings where randomization is considered unethical or infeasible

## Potential uses of RWD in effectiveness studies

- Facilitate pragmatic trials/large simple trials embedded in healthcare systems
- External control arm for a single arm trial
- Additional control data (hybrid control arm) for an RCT
- Observational comparative effectiveness analyses

## Challenges to validity of RWE from a regulatory perspective

- Lack of alignment of trial and RWD inclusions/exclusion criteria
- Lack of alignment of trial and RWD definitions for key data elements (treatments, outcomes, confounders, etc)
- Lack of capture of endpoints
- Missing data
- Channeling bias and confounding

# FDA considerations for use of RWD

- Are the data fit for use?
  - ▶ Consideration of data quality issues
  - ▶ Missing data due to porosity of EHR
- Is the study design adequate to provide evidence?
  - ▶ Sources of bias
- Does the study conduct meet FDA regulatory requirements?
  - ▶ Study monitoring
  - ▶ Data integrity

<https://www.fda.gov/media/120060/download>

# Outline

Overview of the structure of EHR data

Extracting data elements from the EHR

Missing data issues

Correcting for bias due to EHR data errors

FDA Framework for Real World Evidence

Conclusions

# Exploring EHR data

- If you are interested in exploring EHR data there are a number of sources available online
- **MIMIC IV:** publically available data on 40,000 critical care patients
  - ▶ <https://mimic.physionet.org>
  - ▶ Requires DUA for full data access
- **healthdata.gov:** open access data from the US government
  - ▶ Includes data from many sources including Medicare claims
  - ▶ Some data sets are limited to aggregate data
  - ▶ Medicare PUF include individual-level data but not suitable for research

## Concluding thoughts

- Due to financial incentives and operational efficiencies, EHR will become the dominant mode of clinical/administrative documentation of health encounters
- This creates a vast research resource but also requires knowledge of its complexities to use appropriately
- A key component of data science is expert knowledge about data sources
- To effectively use EHR data we (statisticians) must be willing to learn about where these data come from and how they are used clinically/administratively
- We wouldn't analyze observational data without reading the protocol!

## Recommendations

- Engaging with clinicians, coders, informaticians allows us to
  - ▶ Understand data quality
  - ▶ Make smart choices about when and how EHR data can be used
  - ▶ Identify appropriate methods to mitigate limitations
  - ▶ Develop new statistical methods to fill gaps in available methodology
- EHR data can be messy but don't despair!
- Staying engaged in the research process from data extraction through analysis, interpretation, and reporting of results ensures higher quality research and gives us a seat at the table to help improve processes for the future

# Acknowledgments



- Jinbo Chen
- Yong Chen
- Grace Choi
- Jessica Chubak
- Joanna Harton
- Jing Huang
- Arman Oganisian
- Jessie Tong
- Jianqiao Wang
- Weiwei Zhu

ASA Council of Chapters

Rebecca Hubbard, PhD

[rhubb@upenn.edu](mailto:rhubb@upenn.edu)

<https://www.med.upenn.edu/ehr-stats/>



Perelman  
School of Medicine  
UNIVERSITY of PENNSYLVANIA